535 related articles for article (PubMed ID: 22733891)
21. Comparison of Dynamic Phase Enhancement of Hepatocellular Carcinoma Using Gadoxetate Disodium vs Gadobenate Dimeglumine.
Tirkes T; Mehta P; Aisen AM; Lall C; Akisik F
J Comput Assist Tomogr; 2015; 39(4):479-82. PubMed ID: 25783800
[TBL] [Abstract][Full Text] [Related]
22. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine.
Pediconi F; Catalano C; Padula S; Roselli A; Dominelli V; Cagioli S; Kirchin MA; Pirovano G; Passariello R
AJR Am J Roentgenol; 2008 Nov; 191(5):1339-46. PubMed ID: 18941066
[TBL] [Abstract][Full Text] [Related]
23. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.
Yeom SK; Byun JH; Kim HJ; Park SH; Kim N; Shin YM; Kim PN
Magn Reson Imaging; 2013 Jul; 31(6):911-7. PubMed ID: 23598063
[TBL] [Abstract][Full Text] [Related]
24. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
[TBL] [Abstract][Full Text] [Related]
25. Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine?
Vernuccio F; Cannella R; Gozzo C; Greco V; Midiri M; Furlan A; Tang A; Brancatelli G
Abdom Radiol (NY); 2020 Aug; 45(8):2409-2417. PubMed ID: 32435849
[TBL] [Abstract][Full Text] [Related]
26. Predictors of dysplastic nodule diagnosis in patients with liver cirrhosis on unenhanced and gadobenate dimeglumine-enhanced MRI with dynamic and hepatobiliary phase.
Quaia E; De Paoli L; Pizzolato R; Angileri R; Pantano E; Degrassi F; Ukmar M; Cova MA
AJR Am J Roentgenol; 2013 Mar; 200(3):553-62. PubMed ID: 23436844
[TBL] [Abstract][Full Text] [Related]
27. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
Feuerlein S; Gupta RT; Boll DT; Merkle EM
Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
[TBL] [Abstract][Full Text] [Related]
28. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.
Grazioli L; Morana G; Kirchin MA; Caccia P; Romanini L; Bondioni MP; Procacci C; Chiesa A
J Magn Reson Imaging; 2003 May; 17(5):593-602. PubMed ID: 12720270
[TBL] [Abstract][Full Text] [Related]
29. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
[TBL] [Abstract][Full Text] [Related]
31. Hepatic hemangiomas: evaluation of enhancement patterns at dynamic MRI with gadoxetate disodium.
Tamada T; Ito K; Yamamoto A; Sone T; Kanki A; Tanaka F; Higashi H
AJR Am J Roentgenol; 2011 Apr; 196(4):824-30. PubMed ID: 21427331
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
[TBL] [Abstract][Full Text] [Related]
33. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
Thomeer MG; Willemssen FE; Biermann KK; El Addouli H; de Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
[TBL] [Abstract][Full Text] [Related]
34. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
[TBL] [Abstract][Full Text] [Related]
35. Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.
Feuerlein S; Boll DT; Gupta RT; Ringe KI; Marin D; Merkle EM
AJR Am J Roentgenol; 2011 Jan; 196(1):W18-24. PubMed ID: 21178026
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
[TBL] [Abstract][Full Text] [Related]
37. Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging.
Rudolph A; von Knobelsdorff-Brenkenhoff F; Wassmuth R; Prothmann M; Utz W; Schulz-Menger J
J Magn Reson Imaging; 2014 May; 39(5):1153-60. PubMed ID: 24151119
[TBL] [Abstract][Full Text] [Related]
38. Hyperintense lesions on gadoxetate disodium-enhanced hepatobiliary phase imaging.
Kim MJ; Rhee HJ; Jeong HT
AJR Am J Roentgenol; 2012 Nov; 199(5):W575-86. PubMed ID: 23096201
[TBL] [Abstract][Full Text] [Related]
39. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
[TBL] [Abstract][Full Text] [Related]
40. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
